Loading…

Safety, Pharmacokinetics, and Pharmacodynamics of a First-in-Class ClC-1 Inhibitor to Enhance Muscle Excitability: Phase I Randomized Controlled Trial

NMD670 is a first-in-class inhibitor of skeletal muscle-specific chloride channel ClC-1, developed to improve muscle weakness and fatigue in neuromuscular diseases. Preclinical studies show that ClC-1 inhibition enhances muscle excitability, improving muscle contractility and strength. We describe t...

Full description

Saved in:
Bibliographic Details
Published in:Clinical pharmacology and therapeutics 2024-12
Main Authors: Ruijs, Titia Q, de Cuba, Catherine M K E, Heuberger, Jules A A C, Hutchison, John, Bold, Jane, Grønnebæk, Thomas S, Jensen, Klaus G, Chin, Eva, Quiroz, Jorge A, Petersen, Thomas K, Flagstad, Peter, de Kam, Marieke L, van Esdonk, Michiel J, Klaassen, Erica, Doll, Robert J, Koopmans, Ingrid W, de Goede, Annika A, Aulin, Linda B S, Pedersen, Thomas H, Groeneveld, Geert Jan
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue
container_start_page
container_title Clinical pharmacology and therapeutics
container_volume
creator Ruijs, Titia Q
de Cuba, Catherine M K E
Heuberger, Jules A A C
Hutchison, John
Bold, Jane
Grønnebæk, Thomas S
Jensen, Klaus G
Chin, Eva
Quiroz, Jorge A
Petersen, Thomas K
Flagstad, Peter
de Kam, Marieke L
van Esdonk, Michiel J
Klaassen, Erica
Doll, Robert J
Koopmans, Ingrid W
de Goede, Annika A
Aulin, Linda B S
Pedersen, Thomas H
Groeneveld, Geert Jan
description NMD670 is a first-in-class inhibitor of skeletal muscle-specific chloride channel ClC-1, developed to improve muscle weakness and fatigue in neuromuscular diseases. Preclinical studies show that ClC-1 inhibition enhances muscle excitability, improving muscle contractility and strength. We describe the first-in-human, randomized, double-blind, placebo-controlled study, which evaluated the safety, pharmacokinetics, and pharmacodynamics of single and multiple doses of NMD670 in healthy male and female subjects. Single-ascending doses (50-1,600 mg) were administered in a (partial) cross-over design; multiple-ascending doses (200-600 mg q.d.; 400 mg b.i.d.) were administered in a parallel design. Differences in pharmacokinetics between males/females and fed/fasted states were evaluated. Pharmacodynamic effects were evaluated using muscle velocity recovery cycles (MVRC) and analyzed using mixed-effects modeling. NMD670 was generally safe and well-tolerated in healthy subjects, with the only dose-related adverse event being myotonia occurring at the highest dose levels tested (single dose of 1,200, and 1,600 mg). Moreover, NMD670 significantly increased the following MVRC parameters after a single dose of 1,200 mg compared with placebo: early supernormality (estimated difference (ED) 2.04; 95% confidence interval (CI) 0.379, 3.70; P = 0.0242); early supernormality after 5 conditioning stimuli (ED 2.51; 95%CI 0.599, 4.41; P = 0.0177); supernormality at 20 ms (ED 2.78; 95%CI 1.377, 4.181; P = 0.0021). Importantly, the results of this study indicate pharmacological target engagement at well-tolerated dose levels in healthy subjects; firstly, because myotonia was an expected exaggerated on-target pharmacological effect, and secondly, because the effects on MVRC indicate increased muscle cell excitability. This study in healthy subjects indicates proof-of-mechanism and provides a solid base for translation to patients with neuromuscular diseases.
format article
fullrecord <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_39651850</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>39651850</sourcerecordid><originalsourceid>FETCH-pubmed_primary_396518503</originalsourceid><addsrcrecordid>eNqFj01KA0EUhBtBTPy5grwDpGHGscPEbTPBLASJ2Yc3PT3M0_4J_TrgeBG3nsWTOYK6dVXFR1FFnYh5qaobuVSVmolz5ueiKG5XdX0mZtVqqcpaFXPx_oS9zeMCHgdMHk18oWAzGV4Ahu6PdmNAP1GIPSCsKXGWFKR2yAzaaVnCJgzUUo4JcoQmDBiMhYcjG2eheTWUsSVHebz7LmX7-bGB7TQRPb3ZDnQMOUXnJrtLhO5SnPbo2F796IW4Xjc7fS8Px9bbbn9I5DGN-98n1b-BL4bQVhs</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Safety, Pharmacokinetics, and Pharmacodynamics of a First-in-Class ClC-1 Inhibitor to Enhance Muscle Excitability: Phase I Randomized Controlled Trial</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>Ruijs, Titia Q ; de Cuba, Catherine M K E ; Heuberger, Jules A A C ; Hutchison, John ; Bold, Jane ; Grønnebæk, Thomas S ; Jensen, Klaus G ; Chin, Eva ; Quiroz, Jorge A ; Petersen, Thomas K ; Flagstad, Peter ; de Kam, Marieke L ; van Esdonk, Michiel J ; Klaassen, Erica ; Doll, Robert J ; Koopmans, Ingrid W ; de Goede, Annika A ; Aulin, Linda B S ; Pedersen, Thomas H ; Groeneveld, Geert Jan</creator><creatorcontrib>Ruijs, Titia Q ; de Cuba, Catherine M K E ; Heuberger, Jules A A C ; Hutchison, John ; Bold, Jane ; Grønnebæk, Thomas S ; Jensen, Klaus G ; Chin, Eva ; Quiroz, Jorge A ; Petersen, Thomas K ; Flagstad, Peter ; de Kam, Marieke L ; van Esdonk, Michiel J ; Klaassen, Erica ; Doll, Robert J ; Koopmans, Ingrid W ; de Goede, Annika A ; Aulin, Linda B S ; Pedersen, Thomas H ; Groeneveld, Geert Jan</creatorcontrib><description>NMD670 is a first-in-class inhibitor of skeletal muscle-specific chloride channel ClC-1, developed to improve muscle weakness and fatigue in neuromuscular diseases. Preclinical studies show that ClC-1 inhibition enhances muscle excitability, improving muscle contractility and strength. We describe the first-in-human, randomized, double-blind, placebo-controlled study, which evaluated the safety, pharmacokinetics, and pharmacodynamics of single and multiple doses of NMD670 in healthy male and female subjects. Single-ascending doses (50-1,600 mg) were administered in a (partial) cross-over design; multiple-ascending doses (200-600 mg q.d.; 400 mg b.i.d.) were administered in a parallel design. Differences in pharmacokinetics between males/females and fed/fasted states were evaluated. Pharmacodynamic effects were evaluated using muscle velocity recovery cycles (MVRC) and analyzed using mixed-effects modeling. NMD670 was generally safe and well-tolerated in healthy subjects, with the only dose-related adverse event being myotonia occurring at the highest dose levels tested (single dose of 1,200, and 1,600 mg). Moreover, NMD670 significantly increased the following MVRC parameters after a single dose of 1,200 mg compared with placebo: early supernormality (estimated difference (ED) 2.04; 95% confidence interval (CI) 0.379, 3.70; P = 0.0242); early supernormality after 5 conditioning stimuli (ED 2.51; 95%CI 0.599, 4.41; P = 0.0177); supernormality at 20 ms (ED 2.78; 95%CI 1.377, 4.181; P = 0.0021). Importantly, the results of this study indicate pharmacological target engagement at well-tolerated dose levels in healthy subjects; firstly, because myotonia was an expected exaggerated on-target pharmacological effect, and secondly, because the effects on MVRC indicate increased muscle cell excitability. This study in healthy subjects indicates proof-of-mechanism and provides a solid base for translation to patients with neuromuscular diseases.</description><identifier>EISSN: 1532-6535</identifier><identifier>PMID: 39651850</identifier><language>eng</language><publisher>United States</publisher><ispartof>Clinical pharmacology and therapeutics, 2024-12</ispartof><rights>2024 The Author(s). Clinical Pharmacology &amp; Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0002-1060-4989 ; 0009-0007-2998-708X ; 0000-0001-8159-0273 ; 0000-0003-4199-9781 ; 0000-0003-4840-5704 ; 0000-0001-7202-5088 ; 0000-0001-8510-5722 ; 0000-0002-7551-9072 ; 0000-0002-4655-6667 ; 0009-0003-2552-1312 ; 0000-0002-8261-924X ; 0000-0003-0089-1846 ; 0000-0002-1549-6753</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39651850$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ruijs, Titia Q</creatorcontrib><creatorcontrib>de Cuba, Catherine M K E</creatorcontrib><creatorcontrib>Heuberger, Jules A A C</creatorcontrib><creatorcontrib>Hutchison, John</creatorcontrib><creatorcontrib>Bold, Jane</creatorcontrib><creatorcontrib>Grønnebæk, Thomas S</creatorcontrib><creatorcontrib>Jensen, Klaus G</creatorcontrib><creatorcontrib>Chin, Eva</creatorcontrib><creatorcontrib>Quiroz, Jorge A</creatorcontrib><creatorcontrib>Petersen, Thomas K</creatorcontrib><creatorcontrib>Flagstad, Peter</creatorcontrib><creatorcontrib>de Kam, Marieke L</creatorcontrib><creatorcontrib>van Esdonk, Michiel J</creatorcontrib><creatorcontrib>Klaassen, Erica</creatorcontrib><creatorcontrib>Doll, Robert J</creatorcontrib><creatorcontrib>Koopmans, Ingrid W</creatorcontrib><creatorcontrib>de Goede, Annika A</creatorcontrib><creatorcontrib>Aulin, Linda B S</creatorcontrib><creatorcontrib>Pedersen, Thomas H</creatorcontrib><creatorcontrib>Groeneveld, Geert Jan</creatorcontrib><title>Safety, Pharmacokinetics, and Pharmacodynamics of a First-in-Class ClC-1 Inhibitor to Enhance Muscle Excitability: Phase I Randomized Controlled Trial</title><title>Clinical pharmacology and therapeutics</title><addtitle>Clin Pharmacol Ther</addtitle><description>NMD670 is a first-in-class inhibitor of skeletal muscle-specific chloride channel ClC-1, developed to improve muscle weakness and fatigue in neuromuscular diseases. Preclinical studies show that ClC-1 inhibition enhances muscle excitability, improving muscle contractility and strength. We describe the first-in-human, randomized, double-blind, placebo-controlled study, which evaluated the safety, pharmacokinetics, and pharmacodynamics of single and multiple doses of NMD670 in healthy male and female subjects. Single-ascending doses (50-1,600 mg) were administered in a (partial) cross-over design; multiple-ascending doses (200-600 mg q.d.; 400 mg b.i.d.) were administered in a parallel design. Differences in pharmacokinetics between males/females and fed/fasted states were evaluated. Pharmacodynamic effects were evaluated using muscle velocity recovery cycles (MVRC) and analyzed using mixed-effects modeling. NMD670 was generally safe and well-tolerated in healthy subjects, with the only dose-related adverse event being myotonia occurring at the highest dose levels tested (single dose of 1,200, and 1,600 mg). Moreover, NMD670 significantly increased the following MVRC parameters after a single dose of 1,200 mg compared with placebo: early supernormality (estimated difference (ED) 2.04; 95% confidence interval (CI) 0.379, 3.70; P = 0.0242); early supernormality after 5 conditioning stimuli (ED 2.51; 95%CI 0.599, 4.41; P = 0.0177); supernormality at 20 ms (ED 2.78; 95%CI 1.377, 4.181; P = 0.0021). Importantly, the results of this study indicate pharmacological target engagement at well-tolerated dose levels in healthy subjects; firstly, because myotonia was an expected exaggerated on-target pharmacological effect, and secondly, because the effects on MVRC indicate increased muscle cell excitability. This study in healthy subjects indicates proof-of-mechanism and provides a solid base for translation to patients with neuromuscular diseases.</description><issn>1532-6535</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNqFj01KA0EUhBtBTPy5grwDpGHGscPEbTPBLASJ2Yc3PT3M0_4J_TrgeBG3nsWTOYK6dVXFR1FFnYh5qaobuVSVmolz5ueiKG5XdX0mZtVqqcpaFXPx_oS9zeMCHgdMHk18oWAzGV4Ahu6PdmNAP1GIPSCsKXGWFKR2yAzaaVnCJgzUUo4JcoQmDBiMhYcjG2eheTWUsSVHebz7LmX7-bGB7TQRPb3ZDnQMOUXnJrtLhO5SnPbo2F796IW4Xjc7fS8Px9bbbn9I5DGN-98n1b-BL4bQVhs</recordid><startdate>20241209</startdate><enddate>20241209</enddate><creator>Ruijs, Titia Q</creator><creator>de Cuba, Catherine M K E</creator><creator>Heuberger, Jules A A C</creator><creator>Hutchison, John</creator><creator>Bold, Jane</creator><creator>Grønnebæk, Thomas S</creator><creator>Jensen, Klaus G</creator><creator>Chin, Eva</creator><creator>Quiroz, Jorge A</creator><creator>Petersen, Thomas K</creator><creator>Flagstad, Peter</creator><creator>de Kam, Marieke L</creator><creator>van Esdonk, Michiel J</creator><creator>Klaassen, Erica</creator><creator>Doll, Robert J</creator><creator>Koopmans, Ingrid W</creator><creator>de Goede, Annika A</creator><creator>Aulin, Linda B S</creator><creator>Pedersen, Thomas H</creator><creator>Groeneveld, Geert Jan</creator><scope>NPM</scope><orcidid>https://orcid.org/0000-0002-1060-4989</orcidid><orcidid>https://orcid.org/0009-0007-2998-708X</orcidid><orcidid>https://orcid.org/0000-0001-8159-0273</orcidid><orcidid>https://orcid.org/0000-0003-4199-9781</orcidid><orcidid>https://orcid.org/0000-0003-4840-5704</orcidid><orcidid>https://orcid.org/0000-0001-7202-5088</orcidid><orcidid>https://orcid.org/0000-0001-8510-5722</orcidid><orcidid>https://orcid.org/0000-0002-7551-9072</orcidid><orcidid>https://orcid.org/0000-0002-4655-6667</orcidid><orcidid>https://orcid.org/0009-0003-2552-1312</orcidid><orcidid>https://orcid.org/0000-0002-8261-924X</orcidid><orcidid>https://orcid.org/0000-0003-0089-1846</orcidid><orcidid>https://orcid.org/0000-0002-1549-6753</orcidid></search><sort><creationdate>20241209</creationdate><title>Safety, Pharmacokinetics, and Pharmacodynamics of a First-in-Class ClC-1 Inhibitor to Enhance Muscle Excitability: Phase I Randomized Controlled Trial</title><author>Ruijs, Titia Q ; de Cuba, Catherine M K E ; Heuberger, Jules A A C ; Hutchison, John ; Bold, Jane ; Grønnebæk, Thomas S ; Jensen, Klaus G ; Chin, Eva ; Quiroz, Jorge A ; Petersen, Thomas K ; Flagstad, Peter ; de Kam, Marieke L ; van Esdonk, Michiel J ; Klaassen, Erica ; Doll, Robert J ; Koopmans, Ingrid W ; de Goede, Annika A ; Aulin, Linda B S ; Pedersen, Thomas H ; Groeneveld, Geert Jan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-pubmed_primary_396518503</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ruijs, Titia Q</creatorcontrib><creatorcontrib>de Cuba, Catherine M K E</creatorcontrib><creatorcontrib>Heuberger, Jules A A C</creatorcontrib><creatorcontrib>Hutchison, John</creatorcontrib><creatorcontrib>Bold, Jane</creatorcontrib><creatorcontrib>Grønnebæk, Thomas S</creatorcontrib><creatorcontrib>Jensen, Klaus G</creatorcontrib><creatorcontrib>Chin, Eva</creatorcontrib><creatorcontrib>Quiroz, Jorge A</creatorcontrib><creatorcontrib>Petersen, Thomas K</creatorcontrib><creatorcontrib>Flagstad, Peter</creatorcontrib><creatorcontrib>de Kam, Marieke L</creatorcontrib><creatorcontrib>van Esdonk, Michiel J</creatorcontrib><creatorcontrib>Klaassen, Erica</creatorcontrib><creatorcontrib>Doll, Robert J</creatorcontrib><creatorcontrib>Koopmans, Ingrid W</creatorcontrib><creatorcontrib>de Goede, Annika A</creatorcontrib><creatorcontrib>Aulin, Linda B S</creatorcontrib><creatorcontrib>Pedersen, Thomas H</creatorcontrib><creatorcontrib>Groeneveld, Geert Jan</creatorcontrib><collection>PubMed</collection><jtitle>Clinical pharmacology and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ruijs, Titia Q</au><au>de Cuba, Catherine M K E</au><au>Heuberger, Jules A A C</au><au>Hutchison, John</au><au>Bold, Jane</au><au>Grønnebæk, Thomas S</au><au>Jensen, Klaus G</au><au>Chin, Eva</au><au>Quiroz, Jorge A</au><au>Petersen, Thomas K</au><au>Flagstad, Peter</au><au>de Kam, Marieke L</au><au>van Esdonk, Michiel J</au><au>Klaassen, Erica</au><au>Doll, Robert J</au><au>Koopmans, Ingrid W</au><au>de Goede, Annika A</au><au>Aulin, Linda B S</au><au>Pedersen, Thomas H</au><au>Groeneveld, Geert Jan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety, Pharmacokinetics, and Pharmacodynamics of a First-in-Class ClC-1 Inhibitor to Enhance Muscle Excitability: Phase I Randomized Controlled Trial</atitle><jtitle>Clinical pharmacology and therapeutics</jtitle><addtitle>Clin Pharmacol Ther</addtitle><date>2024-12-09</date><risdate>2024</risdate><eissn>1532-6535</eissn><abstract>NMD670 is a first-in-class inhibitor of skeletal muscle-specific chloride channel ClC-1, developed to improve muscle weakness and fatigue in neuromuscular diseases. Preclinical studies show that ClC-1 inhibition enhances muscle excitability, improving muscle contractility and strength. We describe the first-in-human, randomized, double-blind, placebo-controlled study, which evaluated the safety, pharmacokinetics, and pharmacodynamics of single and multiple doses of NMD670 in healthy male and female subjects. Single-ascending doses (50-1,600 mg) were administered in a (partial) cross-over design; multiple-ascending doses (200-600 mg q.d.; 400 mg b.i.d.) were administered in a parallel design. Differences in pharmacokinetics between males/females and fed/fasted states were evaluated. Pharmacodynamic effects were evaluated using muscle velocity recovery cycles (MVRC) and analyzed using mixed-effects modeling. NMD670 was generally safe and well-tolerated in healthy subjects, with the only dose-related adverse event being myotonia occurring at the highest dose levels tested (single dose of 1,200, and 1,600 mg). Moreover, NMD670 significantly increased the following MVRC parameters after a single dose of 1,200 mg compared with placebo: early supernormality (estimated difference (ED) 2.04; 95% confidence interval (CI) 0.379, 3.70; P = 0.0242); early supernormality after 5 conditioning stimuli (ED 2.51; 95%CI 0.599, 4.41; P = 0.0177); supernormality at 20 ms (ED 2.78; 95%CI 1.377, 4.181; P = 0.0021). Importantly, the results of this study indicate pharmacological target engagement at well-tolerated dose levels in healthy subjects; firstly, because myotonia was an expected exaggerated on-target pharmacological effect, and secondly, because the effects on MVRC indicate increased muscle cell excitability. This study in healthy subjects indicates proof-of-mechanism and provides a solid base for translation to patients with neuromuscular diseases.</abstract><cop>United States</cop><pmid>39651850</pmid><orcidid>https://orcid.org/0000-0002-1060-4989</orcidid><orcidid>https://orcid.org/0009-0007-2998-708X</orcidid><orcidid>https://orcid.org/0000-0001-8159-0273</orcidid><orcidid>https://orcid.org/0000-0003-4199-9781</orcidid><orcidid>https://orcid.org/0000-0003-4840-5704</orcidid><orcidid>https://orcid.org/0000-0001-7202-5088</orcidid><orcidid>https://orcid.org/0000-0001-8510-5722</orcidid><orcidid>https://orcid.org/0000-0002-7551-9072</orcidid><orcidid>https://orcid.org/0000-0002-4655-6667</orcidid><orcidid>https://orcid.org/0009-0003-2552-1312</orcidid><orcidid>https://orcid.org/0000-0002-8261-924X</orcidid><orcidid>https://orcid.org/0000-0003-0089-1846</orcidid><orcidid>https://orcid.org/0000-0002-1549-6753</orcidid></addata></record>
fulltext fulltext
identifier EISSN: 1532-6535
ispartof Clinical pharmacology and therapeutics, 2024-12
issn 1532-6535
language eng
recordid cdi_pubmed_primary_39651850
source Wiley-Blackwell Read & Publish Collection
title Safety, Pharmacokinetics, and Pharmacodynamics of a First-in-Class ClC-1 Inhibitor to Enhance Muscle Excitability: Phase I Randomized Controlled Trial
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T08%3A26%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety,%20Pharmacokinetics,%20and%20Pharmacodynamics%20of%20a%20First-in-Class%20ClC-1%20Inhibitor%20to%20Enhance%20Muscle%20Excitability:%20Phase%C2%A0I%20Randomized%20Controlled%20Trial&rft.jtitle=Clinical%20pharmacology%20and%20therapeutics&rft.au=Ruijs,%20Titia%20Q&rft.date=2024-12-09&rft.eissn=1532-6535&rft_id=info:doi/&rft_dat=%3Cpubmed%3E39651850%3C/pubmed%3E%3Cgrp_id%3Ecdi_FETCH-pubmed_primary_396518503%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/39651850&rfr_iscdi=true